TD-0903

DRUG2 trials

Sponsors

Theravance Biopharma

Conditions

Acute Lung Injury (ALI) Associated With COVID-19Inflammatory Lung Conditions Associated With COVID-19Lung Inflammation Associated With COVID-19

Phase 1

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

CompletedNCT04350736

Theravance BiopharmaAcute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19

Start: 2020-04-23End: 2020-07-01Updated: 2021-07-01

Phase 2

TD-0903 for ALI Associated With COVID-19

CompletedNCT04402866

Theravance BiopharmaAcute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19

Start: 2020-06-24End: 2021-04-21Updated: 2022-03-17

Related Papers

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

BMJ Open Respiratory Research2023-07-017 citations